Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)

NCT02702401 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

413

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Placebo
OTHER: Best Supportive Care

Sponsor

Merck Sharp & Dohme LLC